<DOC>
	<DOC>NCT00575471</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy response of rivoglitazone HCl on the change in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.</brief_summary>
	<brief_title>Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>type 2 diabetes mellitus HbA1c &gt;6.5% and &lt;10% FPG &gt;126 mg/dL (7mmol/L) and &lt;270 mg/dL (15 mmol/L) history of type 1 diabetes history of ketoacidosis current insulin therapy Cpeptide &lt;0.5ng/mL impaired hepatic function CHF or history of CHF (NYHA stage I IV) uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>rivoglitazone HCl</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>peroxisome proliferator-activated receptor gamma (PPARgamma)</keyword>
	<keyword>diabetes mellitus, type 2</keyword>
</DOC>